Chiesi Farmaceutici

Chiesi Global Rare Diseases Announces Results from Study Evaluating Economic Burden of Rare Diseases and Launches Second Annual #WeWearStripes Campaign on Rare Disease Day

Retrieved on:

Lunedì, Febbraio 28, 2022

The company is also recognizing Rare Disease Day 2022 with the launch of the second annual #WeWearStripes for the Rare Ones social media campaign.

Key Points:

The company is also recognizing Rare Disease Day 2022 with the launch of the second annual #WeWearStripes for the Rare Ones social media campaign.
"Every year Rare Disease Day brings together more than 300 million people affected by rare diseases around the world in a collective effort to build broader awareness and call for new treatment options," said Giacomo Chiesi, head of Chiesi Global Rare Diseases and co-author of the study.
Results demonstrated that rare diseases impose a substantial economic burden that can be reduced with availability of new treatments.
"The results of this study are clear - access to therapies for people living with rare diseases generates significant value for society.

Chiesi USA certified as a Great Place to Work® in 2021

Retrieved on:

Giovedì, Febbraio 24, 2022

(key-A-zee), a Cary-based specialty pharmaceutical company, has earned the Great Place to Work Certification for 2021 in the U.S., following its first recognition in 2019.

Key Points:

(key-A-zee), a Cary-based specialty pharmaceutical company, has earned the Great Place to Work Certification for 2021 in the U.S., following its first recognition in 2019.
In total, 92% of employee respondents agreed Chiesi USA is a great place to work, and the companys Trust Index average increased from 86% in 2019 to 89% in 2021.
Our team is humbled and incredibly grateful to be recognized again as a Great Place to Work by this respected organization, said Allyson Stevens, Senior Director of HR at Chiesi USA.
In addition to the Great Place to Work Certification, Chiesi USA received the Top Employer in the U.S. certification for the last seven years by the Top Employers Institute.

Inhibrx Announces Amended Loan Agreement with Oxford

Retrieved on:

Martedì, Febbraio 22, 2022

"Oxford has been a supportive partner throughout our evolution and transformation as a company and we are pleased to expand the relationship."

Key Points:

"Oxford has been a supportive partner throughout our evolution and transformation as a company and we are pleased to expand the relationship."
The terms of the three existing tranches under the loan agreement were modified to align with the four additional tranches.
The repayment schedule provides for interest-only payments until March 2025 with a potential 12-month extension as defined in the agreement.
Inhibrx also issued to Oxford warrants to purchase 40,000 shares of Inhibrx's common stock at a strike price of $45.00 per share.

Chiesi USA Announces New Publication of Post Hoc Analysis on Timing of Ischemic Events in Cardiac Patients and Role of KENGREAL® (cangrelor) in Reducing Risk

Retrieved on:

Martedì, Gennaio 25, 2022

The analysis is published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association, and can be accessed here .

Key Points:

The analysis is published in Circulation: Cardiovascular Interventions, a journal of the American Heart Association, and can be accessed here .
There was no rebound increase in cardiovascular events during the time period in which patients were transitioned from KENGREAL to an oral P2Y12 inhibitor.
The most common early event was SCAI-MI (44%), followed by ARC-ST (7%), IDR (7%) and death (5%).
This analysis also characterizes a post hoc secondary composite endpoint described earlier that was not part of the original trial design.

Chiesi USA, Inc. Receives Top Employer in the U.S. Certification for 2022

Retrieved on:

Lunedì, Gennaio 24, 2022

(key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the company has been named a Top Employer in the United States for the seventh year in a row.

Key Points:

(key-A-zee), the U.S. affiliate of Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced today that the company has been named a Top Employer in the United States for the seventh year in a row.
The entire Chiesi USA team celebrates this certification as we continue our people-first commitment that allows us to achieve this high standard year after year.
In addition to the U.S. certification, Chiesi Group achieved Top Employer Europe status for the 10th consecutive year and Top Employer in Italy status for the 14th year in a row.
The Company is a wholly-owned subsidiary of family-owned Chiesi Farmaceutici S.p.A, a global R&D-focused pharmaceutical company based in Parma, Italy.

Inhibrx Announces Initial Phase 1 Dose Escalation Results for INBRX-106, a Novel Hexavalent OX40 Agonist, in Combination with Keytruda® (Pembrolizumab) Along with Updated Single Agent Data

Retrieved on:

Martedì, Gennaio 4, 2022

Additionally, an update on single agent data from Part 1 (single agent dose escalation) and Part 2 (single agent dose expansion) of the trial was provided.

Key Points:

Additionally, an update on single agent data from Part 1 (single agent dose escalation) and Part 2 (single agent dose expansion) of the trial was provided.
INBRX-106 in combination with Keytruda was observed to be well tolerated, with predominantly mild or moderate immune-related toxicities noted.
The maximum administered dose of INBRX-106 was 0.3 mg/kg, at which dose-limiting, immune-related toxicities such as dermatitis were observed.
Accordingly, 0.1 mg/kg dosed every three weeks was determined to be the maximum tolerated dose (MTD) of INBRX-106 in combination with Keytruda.

Chiesi accelerates path toward full sustainability despite COVID-19 pandemic

Retrieved on:

Mercoledì, Giugno 23, 2021

Chiesi Farmaceutici, Pharmaceutical industry

All the companys 2020 activities, data and figures are available in the Chiesi Groups Annual & Sustainability Report 2020, accessible via the dedicated microsite chiesieverystorycounts.com .

Key Points:

All the companys 2020 activities, data and figures are available in the Chiesi Groups Annual & Sustainability Report 2020, accessible via the dedicated microsite chiesieverystorycounts.com .
CARY, N.C., June 23, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), further accelerated its path toward becoming a fully sustainable company, despite an extremely challenging 2020, which was overshadowed by the COVID-19 pandemic.
In addition, Chiesi maintained the production of medical products, especially those which were essential or needed to treat rare diseases.
In 2020, Chiesi dedicated more than 20% of its revenues to R&D, which placed Chiesi as the top Italian pharmaceutical company for number of patents filed.

Chiesi Accelerates Path Toward Full Sustainability Despite Covid-19 Pandemic

Retrieved on:

Mercoledì, Giugno 23, 2021

Research, Environment, Human resources, Professional services, Alternative energy, Energy, Biotechnology, Pharmaceutical, Health, Science, Pharmaceutical industry, Pharmacology, Pharmacy, Chiesi Farmaceutici

Chiesi, the international research-focused pharmaceutical and healthcare Group (Chiesi Group), further accelerated its path toward becoming a fully sustainable company, despite an extremely challenging 2020, which was overshadowed by the Covid-19 pandemic.

Key Points:

Chiesi, the international research-focused pharmaceutical and healthcare Group (Chiesi Group), further accelerated its path toward becoming a fully sustainable company, despite an extremely challenging 2020, which was overshadowed by the Covid-19 pandemic.
In a year unlike any other in the Groups history, Chiesi worked relentlessly to protect patients and ensure their unhindered access to life-saving medical treatments despite the disruptions to supplies and public healthcare services caused by the pandemic.
In addition, Chiesi maintained the production of medical products, especially those which were essential or needed to treat rare diseases.
In 2020 Chiesi dedicated more than 20% of its revenues to R&D, which placed Chiesi as the top Italian pharmaceutical company for number of patents filed.

Chiesi USA announces new organizational leadership for the Chiesi Foundation

Retrieved on:

Giovedì, Maggio 13, 2021

Chiesi Farmaceutici

b'Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr. Paolo Chiesi\nCARY, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), announced that Maria Paola Chiesi was appointed President of the Chiesi Foundation, a non-profit organization established in 2005 as an expression of the corporate social responsibility of the Chiesi Group.

Key Points:

b'Maria Paola Chiesi, former Coordinator of the Foundation since 2010, succeeds Dr. Paolo Chiesi\nCARY, N.C., May 13, 2021 (GLOBE NEWSWIRE) -- Chiesi USA (key-ay-zee), the U.S. affiliate of Chiesi Farmaceutici, an international research-focused healthcare Group (Chiesi Group), announced that Maria Paola Chiesi was appointed President of the Chiesi Foundation, a non-profit organization established in 2005 as an expression of the corporate social responsibility of the Chiesi Group.
I care very much about the Foundation, its commitment beyond company boundaries,\xe2\x80\x9d said Maria Paola Chiesi, Shared Value & Sustainability Head of the Chiesi Group and elect President of the Chiesi Foundation.
The Company is a wholly-owned subsidiary of family-owned Chiesi Farmaceutici S.p.A, a global R&D-focused pharmaceutical company based in Parma, Italy.
Recognized as a Certified B Corporation\xe2\x84\xa2, Chiesi is dedicated to improving the health and well-being of its communities through its employee-led corporate social responsibility program, Chiesi in the Community.

Chiesi Group calls for #ActionOverWords in the fight against climate change

Retrieved on:

Lunedì, Maggio 10, 2021

Chiesi Farmaceutici, Pharmaceutical industry in China

But to date, only a few refer to official standards to measure progress toward their commitments on an individual company level.

Key Points:

But to date, only a few refer to official standards to measure progress toward their commitments on an individual company level.
And they help citizens and policy makers identify those mitigation measures that make the difference.\n\xe2\x80\x9cAt Chiesi, we stand with all those doing their part to halt climate change,\xe2\x80\x9d comments Maria Paola Chiesi, Shared Value & Sustainability Director of Chiesi Group.
The Company is a wholly-owned subsidiary of family-owned Chiesi Farmaceutici S.p.A, a global R&D-focused pharmaceutical company based in Parma, Italy.
For more information, visit www.chiesiusa.com .\nBased in Parma, Italy, Chiesi is an international research-focused pharmaceuticals and healthcare group with over 85 years\xe2\x80\x99 experience, operating in 30 countries with more than 6,000 employees (Chiesi Group).